Cargando…

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis

AIM: Leflunomide is a disease-modifying antirheumatic drug used in therapy for rheumatoid arthritis (RA). Previous studies indicated that oestrogens and androgens may affect the response to leflunomide in RA patients. The synthesis of androgens is regulated by cytochrome CYB5A. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Łączna, Małgorzata, Malinowski, Damian, Paradowska-Gorycka, Agnieszka, Safranow, Krzysztof, Dziedziejko, Violetta, Pawlik, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Pharmacogenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528780/ https://www.ncbi.nlm.nih.gov/pubmed/34160668 http://dx.doi.org/10.1007/s00228-021-03172-3

Ejemplares similares

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
por: Dziedziejko, Violetta, et al.
Publicado: (2011)

VAV1 Gene Polymorphisms in Patients with Rheumatoid Arthritis
por: Pawlik, Andrzej, et al.
Publicado: (2020)

Interleukin-21 gene polymorphism rs2221903 is associated with disease activity in patients with rheumatoid arthritis
por: Malinowski, Damian, et al.
Publicado: (2017)

SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients
por: Pawlik, Andrzej, et al.
Publicado: (2019)

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
por: Wu, Yi, et al.
Publicado: (2021)

IL17A and IL17F gene polymorphisms in patients with rheumatoid arthritis
por: Pawlik, Andrzej, et al.
Publicado: (2016)

PECAM1, COL4A2, PHACTR1, and LMOD1 Gene Polymorphisms in Patients with Unstable Angina
por: Kosiński, Krzysztof, et al.
Publicado: (2022)

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus
por: Kurzawski, Mateusz, et al.
Publicado: (2012)

The Association between CDKAL1 Gene rs10946398 Polymorphism and Post-Transplant Diabetes in Kidney Allograft Recipients Treated with Tacrolimus
por: Dziedziejko, Violetta, et al.
Publicado: (2023)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
por: de Wildt, Saskia N., et al.
Publicado: (2011)

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study
por: Andreassen, Trine Naalsund, et al.
Publicado: (2011)

Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography
por: Banaś, Anna, et al.
Publicado: (2011)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
por: O'Meara, Helen, et al.
Publicado: (2014)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan
por: Shimazawa, R, et al.
Publicado: (2014)

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
por: Trompet, S., et al.
Publicado: (2015)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
por: Vizeli, Patrick, et al.
Publicado: (2017)

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
por: Wattanachai, Nitsupa, et al.
Publicado: (2017)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
por: Liu, Mengyuan, et al.
Publicado: (2020)

Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients
por: Preissner, Sally H., et al.
Publicado: (2021)

PPARG, TMEM163, UBE2E2, and WFS1 Gene Polymorphisms Are Not Significant Risk Factors for Gestational Diabetes in the Polish Population
por: Ustianowski, Przemysław, et al.
Publicado: (2022)

IL-17F Gene rs763780 and IL-17A rs2275913 Polymorphisms in Patients with Periodontitis
por: Mazurek-Mochol, Małgorzata, et al.
Publicado: (2021)

COBLL1 and IRS1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes
por: Ustianowski, Przemyslaw, et al.
Publicado: (2022)

THADA, SDHAF4, and MACF1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes
por: Ustianowski, Przemysław, et al.
Publicado: (2022)

Lack of significant association between selected STAT3 polymorphisms and rheumatoid arthritis in the Polish population
por: Stypińska, Barbara, et al.
Publicado: (2018)

KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis
por: Paradowska-Gorycka, Agnieszka, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgpolh1930a73mb10v3614erqr